Management of virologic failure and HIV drug resistance
SM McCluskey, MJ Siedner… - Infectious Disease Clinics, 2019 - id.theclinics.com
In 2014, the Joint United Nations Programme on HIV and AIDS established global targets
such that 90% of people with HIV will be diagnosed, 90% of those diagnosed will be on …
such that 90% of people with HIV will be diagnosed, 90% of those diagnosed will be on …
[HTML][HTML] Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV
NI Paton, J Musaazi, C Kityo, S Walimbwa… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background The World Health Organization recommends dolutegravir with two
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis
Background Selection of optimal second-line antiretroviral therapy (ART) has important
clinical and programmatic implications. To inform the 2016 revision of the WHO ART …
clinical and programmatic implications. To inform the 2016 revision of the WHO ART …
Adult antiretroviral therapy guidelines 2017
These guidelines are intended as an update to those published in the Southern African
Journal of HIV Medicine in 2014 and the update on when to initiate antiretroviral therapy in …
Journal of HIV Medicine in 2014 and the update on when to initiate antiretroviral therapy in …
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy …
M Aboud, R Kaplan, J Lombaard, F Zhang… - The Lancet infectious …, 2019 - thelancet.com
Background Doubts exist regarding optimal second-line treatment options for HIV-1-infected
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …
[PDF][PDF] Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update
MB Mulaudzi, JF Woods, WDF Venter… - Southern African journal …, 2020 - ajol.info
Key updates ÿ A recommendation for dolutegravir (DTG)-based therapies as the preferred
first-line antiretroviral therapy (ART) option (section 11). ÿ Updated guidelines for second …
first-line antiretroviral therapy (ART) option (section 11). ÿ Updated guidelines for second …
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA) …
NI Paton, J Musaazi, C Kityo, S Walimbwa, A Hoppe… - The Lancet …, 2022 - thelancet.com
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …
Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research
A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled
out in low-income and middle-income countries (LMICs). In studies from predominantly high …
out in low-income and middle-income countries (LMICs). In studies from predominantly high …
Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors
People living with human immunodeficiency virus (HIV) receiving integrase strand transfer
inhibitors (INSTIs) have been reported to experience virological failure in the absence of …
inhibitors (INSTIs) have been reported to experience virological failure in the absence of …
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
Objective: Recycling tenofovir and lamivudine/emtricitabine (XTC) with dolutegravir would
provide a more tolerable, affordable, and scalable second-line regimen than dolutegravir …
provide a more tolerable, affordable, and scalable second-line regimen than dolutegravir …